Health-related quality of life of patients with prostate cancer initiating GnRH agonist therapy: the PRISME study

To compare the evolution of health-related quality of life (HRQoL) over 6 months of GnRH agonist (GnRHa) therapy among age groups for patients with prostate cancer (PCa). PRISME (NCT03516110) was a non-interventional, prospective study conducted in France in patients aged ≥60 years with PCa initiati...

Full description

Saved in:
Bibliographic Details
Published in:The aging male 2024-12, Vol.27 (1), p.2406547
Main Authors: Rozet, François, Hennequin, Christophe, Mongiat-Artus, Pierre, Pello-Leprince-Ringuet, Nathalie, Grandoulier, Anne-Sophie, Roupret, Morgan
Format: Article
Language:English
Subjects:
Age Factors
Age groups
Aged
Aged, 80 and over
Antineoplastic Agents, Hormonal - therapeutic use
Cancer therapies
cognitive function
elderly
Endocrine therapy
France
GnRH agonist
Gonadotropin-Releasing Hormone - agonists
Humans
Male
Mens health
Middle Aged
Prospective Studies
Prostate cancer
Prostatic Neoplasms - drug therapy
Quality of Life
Surveys and Questionnaires
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To compare the evolution of health-related quality of life (HRQoL) over 6 months of GnRH agonist (GnRHa) therapy among age groups for patients with prostate cancer (PCa). PRISME (NCT03516110) was a non-interventional, prospective study conducted in France in patients aged ≥60 years with PCa initiating GnRHa therapy within routine care. HRQoL was evaluated at baseline and after 6 months using the EORTC quality of life in ELDerly cancer patients 14 items (QLQ-ELD14) questionnaire. Cognitive status was assessed using the Mini Mental State Examination (MMSE). Analyses of covariance compared the evolution of the change from baseline of the QLQ-ELD14 scores among age groups. 814 patients were enrolled (245, 60-70 years; 314, 70-75 years; 252, ≥75 years). Slight or no changes were observed in each QLQ-ELD14 dimension between baseline and 6 months, overall and by age. In the primary effectiveness analysis, there was no difference among age groups in the change from baseline in QLQ-ELD14 scores. Baseline cognitive status was lower in the oldest age group, but there were no changes in all age groups. As expected, sexual function declined in all age groups. GnRHa therapy influence on HRQoL, cognition and sexuality appeared independent of age.
ISSN:1368-5538
1473-0790
1473-0790
DOI:10.1080/13685538.2024.2406547